Similarly, the second cohort of mice, bearing control (pcDNA) or ΔNLS IL-33 glioma cells, were monitored until the control mice became symptomatic, ~6 weeks postinjection, at which point all remaining mice were sacrificed and prepared for IHC. This evidence concerns the gene IL33 and central nervous system cancer.